AJP - Lung AJP citation statistics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Lung Cell Mol Physiol (November 9, 2007). doi:10.1152/ajplung.00313.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/2/L152    most recent
00313.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moore, B. B
Right arrow Articles by Hogaboam, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moore, B. B
Right arrow Articles by Hogaboam, C. M.
Submitted on August 7, 2007
Accepted on November 7, 2007

Murine Models of Pulmonary Fibrosis

Bethany B Moore1* and Cory M. Hogaboam2

1 Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States
2 Pathology, University of Michigan, Ann Arbor, Michigan, United States

* To whom correspondence should be addressed. E-mail: bmoore{at}umich.edu.

Human pulmonary fibrosis is characterized by alveolar epithelial cell injury, areas of type II cell hyperplasia, accumulation of fibroblasts and myofibroblasts and the deposition of extracellular matrix proteins. The result is a progressive loss of normal lung architecture and impairment in gas exchange. Pertinent features of the human disease include temporal heterogeneity of the fibrotic lesions, progressive nature of the disease, development of fibrotic foci and in some patients a rapid worsening of symptoms known as an acute exacerbation. No current animal model recapitulates all of these cardinal manifestations of the human disease. However, investigations using murine models have led to the identification of many pathologic cells and mediators that are believed to be important in human disease as well. In this review, we will summarize the characteristics, advantages and disadvantages of many of the currently utilized murine models of pulmonary fibrosis




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Jackson and C. D. Fell
Etanercept for Idiopathic Pulmonary Fibrosis: Lessons on Clinical Trial Design
Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 889 - 891.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Hashimoto, F. Amaya, H. Matsuyama, H. Ueno, S. Kikuchi, M. Tanaka, Y. Watanabe, M. Ebina, A. Ishizaka, S. Tsukita, et al.
Dysregulation of lung injury and repair in moesin-deficient mice treated with intratracheal bleomycin
Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L566 - L574.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
G. Matute-Bello, C. W. Frevert, and T. R. Martin
Animal models of acute lung injury
Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L379 - L399.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Gauldie and M. Kolb
Animal models of pulmonary fibrosis: how far from effective reality?
Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L151 - L151.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.